New Antibiotic Development Alliance

NH Healthwatch Articles: Antibiotic Development News.


HHS Enters into Strategic Alliance
Partnership stimulates pipeline of drugs to treat multi-drug resistant bacterial infections.

Multiple drugs to combat bioterrorism threats and other life-threatening bacterial infections will be developed under a public-private partnership agreement between the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) and AstraZeneca, a global biopharmaceutical company.

The partnership agreement with AstraZeneca uses Other Transaction Authority granted to the Secretary of HHS under the Pandemic and All Hazards Preparedness Act of 2006. The agreement becomes the second such strategic alliance ASPR's Biomedical Advanced Research and Development Authority (BARDA) has forged with a private company to develop a portfolio of drug candidates with dual uses in treating illnesses caused by bioterrorism agents and antibiotic-resistant infections.

Traditionally, BARDA supports development of individual products. Supporting development of multiple drug candidates increases the likelihood that one or more will advance to the level at which the company can apply for U.S. Food and Drug Administration approval of the drug. In addition, novel antibiotics developed under the agreement may become available in the commercial marketplace, which diminishes the federal government's need to stockpile these products for biodefense and reduces long-term costs for taxpayers.

BARDA and AstraZeneca will manage and fund the portfolio over the next five years. In the cost-sharing arrangement, BARDA initially will provide $50 million toward product development and could provide up to a total of $170 million for development of additional products in the portfolio during the five-year period. During joint annual portfolio reviews, BARDA and AstraZeneca will determine which drug candidates move in or out of the portfolio based on technical and financial considerations and each drug candidate's development progress.

The first drug candidate in the portfolio combines two antibiotics, Aztreonam and Avibactam, known together as ATM-AVI. The new drug is being developed to treat Gram-negative infections for which there are currently limited treatment options. Under today's agreement, the company also will conduct studies evaluating ATM-AVI and other antibiotic candidates for use in treating illnesses caused by deadly bioterrorism threats such as meliodosis, glanders and plague.

The European Union's Innovative Medicines Initiative (IMI), a partnership between the European Union and the European pharmaceutical industry, currently is supporting the Phase 2 clinical study of ATM-AVI in Europe under a project called COMBACTE-CARE. The IMI will join BARDA and AstraZeneca in funding additional clinical studies needed to apply for regulatory approval of ATM-AVI.

"This agreement demonstrates our commitment to sustaining the development and approval of new drugs which can help us address our biodefense needs but are also desperately needed to address the rising threat of antibiotic resistance," said BARDA director Robin Robinson, Ph.D. "We are especially excited to be working jointly with IMI to promote the development of new antibiotics. Antibiotic resistance is a global problem, and international collaborations must be part of the solution."

The National Action Plan for Combating Antibiotic-Resistant Bacteria, released in March 2015, called for establishing international collaborations and public-private partnerships to incentivize the development of new therapeutics to counter antibiotic resistance. The plan also called for BARDA to create at least one additional portfolio partnership with a pharmaceutical or biotechnology company by March 2016 to accelerate development of new antibacterial drugs.

CDC has estimated that in the U.S. antibiotic-resistant bacteria are responsible for two million infections and 23,000 deaths annually with an estimated annual economic burden of $35 billion on the healthcare system.

"We have a perfect storm forming with a rise in antibiotic resistant infections at a time when most pharmaceutical companies have decreased or halted investment in antibacterial R&D," Dr. Robinson explained. "We're using our experience in public-private partnerships and unique legislative authority to rejuvenate the interest of pharmaceutical companies in developing such products."

9/16/15

 

Scheduled Events

  Seussical   (9/6-15)
  2001 Space Odyssey   (9/7)
  Muster in the Mountains   (9/7-9)
  Wingzilla   (9/8)
  Canzoniere Grecanico Salentino   (9/9)
  Things [Mom] Taught Me   (9/13-23)
  Reach the Beach   (9/14-15)
  WM Storytelling Festival   (9/14-16)
  Metallak Race   (9/15)
  Mandeville & Richards   (9/15)
  Cohase Film Slam   (9/16)
  Tricycle Grand Prix  (9/16)
  Rodney Crowell   (9/21)
  NH Highland Games   (9/21-23)
  Don Who   (9/22)
  Harvest Celebration   (9/22)
  Health & Wellness Fair   (9/22)
  Jeep Invasion  (9/22)
  Lakes Region Tri Festival   (9/22-23)
  Pat Metheny   (9/26)
  Driving Miss Daisy   (9/27 - 10/6)
  Neko Case   (9/27)
  Shot of JD   (9/28)
  Dixville Half Marathon   (9/29)
  New Hampshire Marathon   (9/29)
  Matthew Odell   (9/30)
  Lincoln Fall Craft Festival   (10/6&7)
  Sparrow Blue & Crowes Pasture   (10/6)
  Oktoberfest  (10/6-7)
  White Mountain Oktoberfest   (10/6-7)
  Fall Foliage Celebration   (10/6-8)
  Sandwich Fair   (10/6-8)
  Paddle the Border   (10/7)
  Lincoln Fall Craft Festival   (10/7-9)
  Shadow Play   (10/10)
  Killer Joe   (10/11-21)
  Greg Brown   (10/12)
  Camping & RV Show   (10/12-14)
  Riverfire & Horrorfest   (10/13)
  Jay Stollman Band   (10/19)
  Murder Dinner Train   (10/19-20)
  Pumpkin Patch Express   (10/19-21)
  All Things Pumpkin   (10/20)
  Ethan Setiawan Band   (10/20)
  Bettye LaVette   (10/26)
  Murder Dinner Train   (10/26-27)
  Pumpkin Patch Express   (10/26-28)
  Berlin Jazz   (10/27)

 ◄ Expanded Calendar ►



Photo Galleries

 

Miss Berlin-Gorham Competition 2012 New England Brewfest 2014 RiverFire, Berlin, NH 2012 Sugar Hill Lupine Festival Gallery 2012 Bristol-Gorham Foliage
Quick Links

 






Business Directory

 

 

                      more ►  

 

 

Attractions

 


Area Attractions opening/closing schedules.


  Alpine Adventures
  Clark's Trading Post
  Cog Railway
  Conway Scenic Railroad
  Flume
  Fort Jefferson Fun Park
  Jericho Mountain ATV Park
  Kancamagus Highway
  Littleton Riverwalk
  Lost River Gorge
  Mountain Meadow Funplex
  Mt. Washington Auto Road
  Polar Caves
  Santa's Village
  Storyland
  Vertical Ventures
  Whale's Tail Water Park
  Woodstock Inn & Brewery

 

more ►  

 

Community Profiles

 

  Bethlehem
  Bretton Woods
  Colebrook
  Conway
  Franconia
  Gorham
  Hanover
  Jackson
  Lebanon
  Lincoln
  Littleton
  North Conway
  Pittsburg
  Plymouth
  Twin Mountain
  Whitefield
  Wolfeboro

more ►  

 

Recreation and Tourism

 

  25 Great Summer Adventures
  Farm To Table Restaurants
  Hiking To Crash Sites
  Little Ski Areas
  Local Movie Theaters
  Local Performance Theaters
  Moose Tours

 

more ►  

 

Other Resources

  NH Cabins & Cottages
  NH Census Info
  NH Data (OEP)
  NH Fishing Reports
  NH Foliage Report
  NH Hiking Trail Conditions
  NH Lottery
  NH Movie Guide
  NH Road Conditions
  NH Ski Reports
  NH Snowmobile Trail Reports
  NH State Parks
  NH Town Officials Directory
  NH Weather
  Summer Safety Tips [.pdf]
  White Mtn. National Forest
  VisitNH.Gov

 

 

 

Copyright 2012-2018 by George C. Jobel, 603-491-4340. All Rights Reserved.